Published in Circulation on May 11, 2010
Pulmonary Hypertension: Assessment of Cell Therapy (PHACeT) | NCT00469027
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) | NCT00452218
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol (2013) 1.96
Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. Circulation (2012) 1.94
Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res (2012) 1.81
MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation (2012) 1.75
Lung ¹⁸F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.42
Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Hum Mutat (2015) 1.38
The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. Am J Respir Cell Mol Biol (2012) 1.34
Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation (2012) 1.27
Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PLoS One (2012) 1.25
Increased TMEM16A-encoded calcium-activated chloride channel activity is associated with pulmonary hypertension. Am J Physiol Cell Physiol (2012) 1.15
Pulmonary arterial hypertension: the clinical syndrome. Circ Res (2014) 1.11
Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report. Am J Respir Crit Care Med (2010) 1.09
Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation. J Biol Chem (2013) 1.07
Metabolomic heterogeneity of pulmonary arterial hypertension. PLoS One (2014) 1.07
Exacerbated pulmonary arterial hypertension and right ventricular hypertrophy in animals with loss of function of extracellular superoxide dismutase. Hypertension (2011) 1.06
PGC1α-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension. Am J Respir Crit Care Med (2013) 1.06
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One (2012) 1.04
Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect. Eur J Clin Invest (2013) 1.03
The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease. FASEB J (2012) 1.01
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells. J Biol Chem (2013) 0.96
Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol (2012) 0.95
Pulmonary arterial hypertension: MR imaging-derived first-pass bolus kinetic parameters are biomarkers for pulmonary hemodynamics, cardiac function, and ventricular remodeling. Radiology (2012) 0.95
mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. FASEB J (2013) 0.94
Hypoxia induces downregulation of PPAR-γ in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-β signaling. Am J Physiol Lung Cell Mol Physiol (2011) 0.93
Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell disease. Circulation (2014) 0.92
MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension. Circ Res (2015) 0.91
Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension. Am J Respir Cell Mol Biol (2010) 0.90
Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ (2013) 0.90
MicroRNAs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol (2015) 0.90
Mitochondrial dynamics in pulmonary arterial hypertension. J Mol Med (Berl) (2015) 0.89
Overview of current therapeutic approaches for pulmonary hypertension. Pulm Circ (2011) 0.89
Oxidative modulation of voltage-gated potassium channels. Antioxid Redox Signal (2013) 0.89
Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. Circulation (2014) 0.89
Protective effects of 10-nitro-oleic acid in a hypoxia-induced murine model of pulmonary hypertension. Am J Respir Cell Mol Biol (2014) 0.88
Enhancer of zeste homolog 2 induces pulmonary artery smooth muscle cell proliferation. PLoS One (2012) 0.88
Peroxisome proliferator-activated receptor gamma (PPARγ) regulates thrombospondin-1 and Nox4 expression in hypoxia-induced human pulmonary artery smooth muscle cell proliferation. Pulm Circ (2012) 0.87
Inactivation of p53 Is Sufficient to Induce Development of Pulmonary Hypertension in Rats. PLoS One (2015) 0.87
Translating MicroRNA Biology in Pulmonary Hypertension: It Will Take More Than "miR" Words. Am J Respir Crit Care Med (2016) 0.87
Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders. Pharmacol Rev (2016) 0.87
Glc-6-PD and PKG contribute to hypoxia-induced decrease in smooth muscle cell contractile phenotype proteins in pulmonary artery. Am J Physiol Lung Cell Mol Physiol (2012) 0.86
C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target. Curr Pharm Des (2010) 0.85
Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocaine-mediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol (2013) 0.85
Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. Am J Respir Crit Care Med (2013) 0.84
Accuracy of Doppler-echocardiographic mean pulmonary artery pressure for diagnosis of pulmonary hypertension. PLoS One (2010) 0.83
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Clin Pharmacol Ther (2014) 0.83
Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2011) 0.83
miR-138 and miR-25 Downregulate MCU, Causing Pulmonary Arterial Hypertension's Cancer Phenotype. Am J Respir Crit Care Med (2016) 0.83
The Robyn Barst Memorial Lecture: Differences between the fetal, newborn, and adult pulmonary circulations: relevance for age-specific therapies (2013 Grover Conference series). Pulm Circ (2014) 0.83
Cardiomyocyte-specific overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced pulmonary hypertension in mice. PLoS One (2012) 0.82
Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. Histopathology (2012) 0.82
Epigenetics: novel mechanism of pulmonary hypertension. Lung (2013) 0.82
PPARγ Ligands Attenuate Hypoxia-Induced Proliferation in Human Pulmonary Artery Smooth Muscle Cells through Modulation of MicroRNA-21. PLoS One (2015) 0.81
Right ventricular failure and pathobiology in patients with congenital heart disease - implications for long-term follow-up. Front Pediatr (2013) 0.80
Endothelin-1 promotes cytoplasmic accumulation of RIP140 through a ET(A)-PLCβ-PKCε pathway. Mol Cell Endocrinol (2011) 0.80
Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood (2016) 0.80
Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension. Pulm Circ (2015) 0.79
The emperor's new clothes: PDE5 and the heart. PLoS One (2015) 0.79
TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. J Med Genet (2013) 0.79
Pulmonary hypertension in Kawasaki disease. Pediatr Cardiol (2012) 0.79
Cell-based therapies in pulmonary hypertension: who, what, and when? Am J Physiol Lung Cell Mol Physiol (2011) 0.78
Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats. Acta Pharmacol Sin (2014) 0.78
Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension. Hypertension (2015) 0.78
Transient but not genetic loss of miR-451 is protective in the development of pulmonary arterial hypertension. Pulm Circ (2013) 0.78
The serotonin transporter promotes a pathological estrogen metabolic pathway in pulmonary hypertension via cytochrome P450 1B1. Pulm Circ (2016) 0.78
MURC deficiency in smooth muscle attenuates pulmonary hypertension. Nat Commun (2016) 0.78
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. Expert Rev Respir Med (2011) 0.77
Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension. Respir Res (2013) 0.77
High-sensitive Troponin T increase after exercise in patients with pulmonary arterial hypertension. BMC Pulm Med (2013) 0.77
Megakaryocytic leukemia 1 (MKL1) regulates hypoxia induced pulmonary hypertension in rats. PLoS One (2014) 0.77
Mechanical stretching stimulates collagen synthesis via down-regulating SO2/AAT1 pathway. Sci Rep (2016) 0.77
Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. PLoS One (2013) 0.77
Attenuated right ventricular energetics evaluated using ¹¹C-acetate PET in patients with pulmonary hypertension. Eur J Nucl Med Mol Imaging (2014) 0.77
Relaxation of human pulmonary arteries by PPARγ agonists. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.77
A mitochondrial redox oxygen sensor in the pulmonary vasculature and ductus arteriosus. Pflugers Arch (2015) 0.76
Serotonin receptors take the TRiPV4 highway in chronic hypoxic pulmonary hypertension. Focus on "TRPV4 channel contributes to serotonin-induced pulmonary vasoconstriction and the enhanced vascular reactivity in chronic hypoxic pulmonary hypertension". Am J Physiol Cell Physiol (2013) 0.76
Spread the word, children are still not "small adults". Pulm Circ (2013) 0.76
Molecular and functional significance of Ca(2+)-activated Cl(-) channels in pulmonary arterial smooth muscle. Pulm Circ (2015) 0.76
Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats. J Anesth (2015) 0.76
Pulmonary hypertension: diagnostic approach and optimal management. CMAJ (2016) 0.75
MicroRNA in the Diseased Pulmonary Vasculature: Implications for the Basic Scientist and Clinician. J Korean Soc Hypertens (2013) 0.75
Paracrine proliferative signaling by senescent cells in world health organization group 3 pulmonary hypertension: age corrupting youth? Circ Res (2011) 0.75
Interdisciplinary networks for the treatment of childhood pulmonary vascular disease: what pulmonary hypertension doctors can learn from pediatric oncologists. Pulm Circ (2013) 0.75
Integrating molecular genetics and systems approaches to pulmonary vascular diseases. Pulm Circ (2013) 0.75
A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension. J Cardiovasc Transl Res (2016) 0.75
NADPH oxidases-do they play a role in TRPC regulation under hypoxia? Pflugers Arch (2015) 0.75
MYPT1 isoforms expressed in HEK293T cells are differentially phosphorylated after GTPγS treatment. J Smooth Muscle Res (2016) 0.75
Effect of Cocaine on Pulmonary Vascular Remodeling and Hemodynamics in Human Immunodeficiency Virus-Transgenic Rats. Am J Respir Cell Mol Biol (2016) 0.75
Endothelial actions of atrial natriuretic peptide prevent pulmonary hypertension in mice. Basic Res Cardiol (2016) 0.75
Engineered Microvessels for the Study of Human Disease. J Biomech Eng (2016) 0.75
Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension. Mol Ther Methods Clin Dev (2016) 0.75
Pulmonary hypertension-"state of the art" management in 2012. Indian Heart J (2012) 0.75
A chocolate a day keeps the doctor away? J Physiol (2011) 0.75
Emerging pathogenetic mechanisms of pulmonary arterial hypertension: nitric oxide and more. Korean Circ J (2011) 0.75
Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension. Pulm Circ (2015) 0.75
Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series). Pulm Circ (2016) 0.75
Hypoxic pulmonary vasoconstriction: from molecular mechanisms to medicine. Chest (2016) 0.75
Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res (2016) 0.75
Time-dependent PPARγ Modulation of HIF-1α Signaling in Hypoxic Pulmonary Artery Smooth Muscle Cells. Am J Med Sci (2016) 0.75
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 13.22
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med (1996) 11.76
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell (2007) 9.20
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet (2000) 7.20
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med (1992) 6.40
Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem (2007) 5.62
Signal transduction by the TGF-beta superfamily. Science (2002) 5.61
Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol (1999) 5.01
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 4.91
Acute oxygen-sensing mechanisms. N Engl J Med (2005) 4.80
An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med (1992) 4.74
Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest (2005) 4.74
Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation (2006) 4.69
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet (2000) 4.42
Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev (2005) 3.80
Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med (1995) 3.70
Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med (2008) 3.67
An epidemiological study of pulmonary arterial hypertension. Eur Respir J (2007) 3.60
Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation (2007) 3.33
Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med (2007) 3.28
Inflammation in pulmonary arterial hypertension. Eur Respir J (2003) 3.18
Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation (1984) 3.15
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med (2008) 3.13
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation (2005) 2.98
Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med (1991) 2.88
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet (2000) 2.82
Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A (2004) 2.79
Association of the metabolic syndrome with pulmonary venous hypertension. Chest (2009) 2.75
An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest (2008) 2.71
Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res (2004) 2.69
Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med (2005) 2.69
Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation (2001) 2.66
Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med (2009) 2.64
Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res (2009) 2.61
Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation (2007) 2.60
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest (2001) 2.59
A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J (2007) 2.53
Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol (1998) 2.52
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med (2005) 2.49
Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A (2007) 2.44
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol (2006) 2.42
Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol (2001) 2.35
Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest (2005) 2.32
Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol (2006) 2.29
Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol (2007) 2.26
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med (1990) 2.25
Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol (2003) 2.25
Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol (2001) 2.24
Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol (2007) 2.23
Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res (2007) 2.19
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation (2008) 2.18
A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation (2009) 2.17
Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res (2006) 2.10
Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol (2007) 2.08
Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res (2004) 2.06
Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res (2001) 2.00
Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension (2004) 1.99
Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation (1994) 1.96
Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant (1996) 1.94
The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl) (2009) 1.94
The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A (2007) 1.93
Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol (2006) 1.93
Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol (2008) 1.90
Pulmonary vascular disease in the developing world. Circulation (2008) 1.90
Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med (2002) 1.89
Increased plasma serotonin in primary pulmonary hypertension. Am J Med (1995) 1.86
Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation (2003) 1.86
High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation (1987) 1.85
Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res (2006) 1.85
Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med (2003) 1.85
Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation (2002) 1.82
Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation (1998) 1.80
Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol (2003) 1.77
Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation (2002) 1.75
Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest (2000) 1.74
Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med (2002) 1.72
Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation (2008) 1.72
Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J (2005) 1.72
Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol (2003) 1.68
Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog Nucleic Acid Res Mol Biol (2001) 1.68
AMP-activated protein kinase: a key stress signaling pathway in the heart. Trends Cardiovasc Med (2005) 1.67
Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration (2007) 1.67
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med (2002) 1.65
Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res (2004) 1.65
Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter. Am J Respir Crit Care Med (2004) 1.64
Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res (1997) 1.63
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation (2005) 1.62
Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation (2004) 1.59
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J (2008) 1.58
Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 5.79
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 3.69
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol (2011) 2.39
Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol (2007) 2.26
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation (2008) 2.18
Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J (2012) 2.16
Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab (2010) 1.85
Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res (2012) 1.81
Role of dynamin-related protein 1 (Drp1)-mediated mitochondrial fission in oxygen sensing and constriction of the ductus arteriosus. Circ Res (2013) 1.67
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation (2005) 1.62
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation (2003) 1.57
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med (2005) 1.56
Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol (2011) 1.48
Cytokine-induced differentiation of multipotent adult progenitor cells into functional smooth muscle cells. J Clin Invest (2006) 1.47
Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin Sci (Lond) (2002) 1.46
Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res (2006) 1.44
Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation (2008) 1.39
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol (2005) 1.29
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat (2011) 1.18
Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation (2010) 1.16
Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 1.12
Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.11
Hypoxic pulmonary vasoconstriction: redox regulation of O2-sensitive K+ channels by a mitochondrial O2-sensor in resistance artery smooth muscle cells. J Mol Cell Cardiol (2004) 1.11
Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart (2011) 1.09
Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease. Hypertension (2012) 1.08
Exacerbated pulmonary arterial hypertension and right ventricular hypertrophy in animals with loss of function of extracellular superoxide dismutase. Hypertension (2011) 1.06
Role of store-operated calcium channels and calcium sensitization in normoxic contraction of the ductus arteriosus. Circulation (2006) 1.04
Generation of oxidants by hypoxic human pulmonary and coronary smooth-muscle cells. Chest (2008) 1.01
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med (2006) 1.01
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation (2003) 1.00
cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol (2004) 1.00
Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J (2012) 0.98
Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther (2008) 0.97
Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse (2011) 0.95
A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One (2012) 0.94
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 0.93
Opposite effects of redox status on membrane potential, cytosolic calcium, and tone in pulmonary arteries and ductus arteriosus. Am J Physiol Lung Cell Mol Physiol (2003) 0.93
Subacute hypoxia decreases voltage-activated potassium channel expression and function in pulmonary artery myocytes. Am J Respir Cell Mol Biol (2004) 0.92
Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics (2006) 0.91
Graded response of K+ current, membrane potential, and [Ca2+]i to hypoxia in pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol (2002) 0.91
Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. Am J Respir Crit Care Med (2002) 0.91
Contribution of the K(Ca) channel to membrane potential and O2 sensitivity is decreased in an ovine PPHN model. Am J Physiol Lung Cell Mol Physiol (2002) 0.90
Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest (2011) 0.88
Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp Lung Res (2010) 0.86
Comparison of 18F-FDG uptake by right ventricular myocardium in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease. Pulm Circ (2012) 0.86
Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. Pulm Circ (2013) 0.85
Advancing clinical trial design in pulmonary hypertension. Pulm Circ (2013) 0.84
A central role for oxygen-sensitive K+ channels and mitochondria in the specialized oxygen-sensing system. Novartis Found Symp (2006) 0.84
Endothelial progenitor cells in pulmonary arterial hypertension. Trends Cardiovasc Med (2010) 0.84
The metabolic basis of vascular oxygen sensing: diversity, compartmentalization, and lessons from cancer. Am J Physiol Heart Circ Physiol (2008) 0.84
Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension. Circulation (2014) 0.84
Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction. Circulation (2005) 0.83
Activation of the EGFR/p38/JNK pathway by mitochondrial-derived hydrogen peroxide contributes to oxygen-induced contraction of ductus arteriosus. J Mol Med (Berl) (2014) 0.83
Acute normoxia increases fetal pulmonary artery endothelial cell cytosolic Ca2+ via Ca2+-induced Ca2+ release. Pediatr Res (2006) 0.82
Genome-wide scan for premature hypertension supports linkage to chromosome 2 in a large Kyrgyz family. Hypertension (2006) 0.82
Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride. J Psychopharmacol (2002) 0.82
Low potassium dextran lung preservation solution reduces reactive oxygen species production. Ann Thorac Surg (2003) 0.81
Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol (2003) 0.81
Clinical, ethical and financial implications of incidental imaging findings: experience from a phase I trial in healthy elderly volunteers. PLoS One (2012) 0.80
Identification and assessment of plasma lysozyme as a putative biomarker of atherosclerosis. Arterioscler Thromb Vasc Biol (2010) 0.80
Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology (Oxford) (2013) 0.79
Regulating cell-based regenerative medicine: the challenges ahead. Regen Med (2014) 0.78
Cannabis and cannabis-based medicines: potential benefits and risks to health. Clin Med (2006) 0.78
Pulmonary hypertension: biomarkers. Handb Exp Pharmacol (2013) 0.78
[Definitions and diagnosis of pulmonary hypertension]. Turk Kardiyol Dern Ars (2014) 0.77
The serotonin transporter: a vehicle to elucidate pulmonary hypertension? Circ Res (2004) 0.76
Pulmonary arterial hypertension and the vasoconstrictive factor: is there still a role for vasodilator testing? Eur Heart J (2003) 0.76
Role of asymmetric methylarginine and connexin 43 in the regulation of pulmonary endothelial function. Pulm Circ (2013) 0.76
Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers). Handb Exp Pharmacol (2013) 0.76
Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension. Am J Respir Crit Care Med (2004) 0.75
Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”. Circulation (2013) 0.75
The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol (2010) 0.75
Assessment of graft patency during coronary artery bypass graft surgery: mitigating the risk. JACC Cardiovasc Imaging (2009) 0.75
Redesign of internal-medicine teaching. N Engl J Med (2010) 0.75
Increased release of serotonin from rat ileum due to dexfenfluramine. Am J Physiol Regul Integr Comp Physiol (2004) 0.75
Redox signal transduction: reductive reasoning. J Lab Clin Med (2002) 0.75